RU2010135831A - Способы, лекарственные формы и наборы для введения зипрасидона без пищи - Google Patents

Способы, лекарственные формы и наборы для введения зипрасидона без пищи Download PDF

Info

Publication number
RU2010135831A
RU2010135831A RU2010135831/15A RU2010135831A RU2010135831A RU 2010135831 A RU2010135831 A RU 2010135831A RU 2010135831/15 A RU2010135831/15 A RU 2010135831/15A RU 2010135831 A RU2010135831 A RU 2010135831A RU 2010135831 A RU2010135831 A RU 2010135831A
Authority
RU
Russia
Prior art keywords
ziprasidone
dosage form
serum
oral dosage
solid oral
Prior art date
Application number
RU2010135831/15A
Other languages
English (en)
Russian (ru)
Inventor
Уильям Джон КУРАТОЛО (US)
Уильям Джон КУРАТОЛО
Скотт Макс ХЕРБИГ (US)
Скотт Макс Хербиг
Авинаш Говинд ТОМБРЕ (US)
Авинаш Говинд Томбре
Джеймин Чандракант ШАХ (US)
Джеймин Чандракант ШАХ
Шерри Л. ШАМБЛИН (US)
Шерри Л. ШАМБЛИН
Тимоти ЛУКАС (US)
Тимоти ЛУКАС
Уильям Бретт КЭЛДУЭЛЛ (US)
Уильям Бретт КЭЛДУЭЛЛ
Дуэйн Томас ФРЕЙЗЕН (US)
Дуэйн Томас ФРЕЙЗЕН
Дэвид Кейт ЛИОН (US)
Дэвид Кейт ЛИОН
Кристофер Донован КРЕЙГ (US)
Кристофер Донован КРЕЙГ
Original Assignee
Пфайзер Инк. (US)
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. (US), Пфайзер Инк. filed Critical Пфайзер Инк. (US)
Publication of RU2010135831A publication Critical patent/RU2010135831A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2010135831/15A 2008-03-07 2009-03-04 Способы, лекарственные формы и наборы для введения зипрасидона без пищи RU2010135831A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3494708P 2008-03-07 2008-03-07
US61/034,947 2008-03-07

Publications (1)

Publication Number Publication Date
RU2010135831A true RU2010135831A (ru) 2012-04-20

Family

ID=40720011

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010135831/15A RU2010135831A (ru) 2008-03-07 2009-03-04 Способы, лекарственные формы и наборы для введения зипрасидона без пищи

Country Status (15)

Country Link
US (1) US20110002989A1 (enExample)
EP (1) EP2280711A1 (enExample)
JP (1) JP2009215293A (enExample)
KR (1) KR20100131477A (enExample)
CN (1) CN102014910A (enExample)
AR (1) AR070964A1 (enExample)
AU (1) AU2009220925A1 (enExample)
BR (1) BRPI0909818A2 (enExample)
CA (1) CA2719115A1 (enExample)
IL (1) IL207792A0 (enExample)
MX (1) MX2010009844A (enExample)
RU (1) RU2010135831A (enExample)
TW (1) TW200950783A (enExample)
WO (1) WO2009109844A1 (enExample)
ZA (1) ZA201005905B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010082855A1 (en) * 2009-01-15 2010-07-22 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation
US9510148B2 (en) * 2009-03-03 2016-11-29 Mobilitie, Llc System and method for wireless communication to permit audience participation
EP2991650A4 (en) * 2013-05-03 2017-01-25 Syndax Pharmaceuticals Inc. Methods for the treatment of cancer
TW201602108A (zh) 2013-07-30 2016-01-16 吉李德康乃狄克公司 脾酪胺酸激酶(Syk)抑制劑之多晶型
NZ715745A (en) 2013-07-30 2017-06-30 Gilead Connecticut Inc Formulation of syk inhibitors
EP3076951B1 (en) * 2013-12-05 2020-09-30 Celal Albayrak Process for the production of drug formulations for oral administration
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
US10474345B2 (en) * 2014-04-04 2019-11-12 Shawn SHEY User interfaces and methods for displaying content
EP3193844A1 (en) * 2014-09-19 2017-07-26 The Procter and Gamble Company Process for making a core with an active coating
JP6796083B2 (ja) 2015-06-09 2020-12-02 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップCapsugel Belgium NV カプセル中の薬剤の噴霧乾燥ディスパーションからの迅速な溶解を達成するための製剤
US11154510B2 (en) 2015-06-11 2021-10-26 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
CN107714669A (zh) * 2016-08-11 2018-02-23 广东东阳光药业有限公司 齐拉西酮缓释剂及其制备方法
EP3672974A1 (en) 2017-08-25 2020-07-01 Gilead Sciences, Inc. Polymorphs of syk inhibitors
JP2022521413A (ja) 2019-02-22 2022-04-07 クロノス バイオ インコーポレイテッド Syk阻害剤としての縮合ピラジンの固体形態

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450748A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
MXPA06002455A (es) * 2003-09-02 2006-08-31 Pfizer Prod Inc Formas de dosificacion de liberacion sostenida de ziprasidona.
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
EP1703898A2 (en) * 2003-12-31 2006-09-27 Alpharma, Inc. Ziprasidone formulations
EP1753400A4 (en) * 2004-06-11 2012-11-28 Reddys Lab Ltd Dr PHARMACEUTICAL FOR ZIPRASIDONE
SG162811A1 (en) * 2005-06-20 2010-07-29 Elan Pharma Int Ltd Nanoparticulate and controlled release compositions comprising aryl- heterocyclic compounds

Also Published As

Publication number Publication date
AR070964A1 (es) 2010-05-19
AU2009220925A1 (en) 2009-09-11
JP2009215293A (ja) 2009-09-24
WO2009109844A1 (en) 2009-09-11
ZA201005905B (en) 2011-11-30
BRPI0909818A2 (pt) 2015-10-06
CN102014910A (zh) 2011-04-13
IL207792A0 (en) 2010-12-30
CA2719115A1 (en) 2009-09-11
EP2280711A1 (en) 2011-02-09
TW200950783A (en) 2009-12-16
US20110002989A1 (en) 2011-01-06
KR20100131477A (ko) 2010-12-15
MX2010009844A (es) 2010-09-30

Similar Documents

Publication Publication Date Title
RU2010135831A (ru) Способы, лекарственные формы и наборы для введения зипрасидона без пищи
US20220184222A1 (en) Bicycle toxin conjugates and uses thereof
JP6845162B2 (ja) ケタミン経皮送達システム
CN103889508B (zh) 用于传递丁丙诺啡的防滥用性粘膜粘附剂装置
Jain et al. Evaluation of efficacy of oral pregabalin in reducing postoperative pain in patients undergoing total knee arthroplasty
US7459430B2 (en) Methods of using ziconotide to treat overactive bladder
JP2009215293A5 (enExample)
JP2020023518A5 (enExample)
US20210196653A1 (en) Delivery Of Esketamine For The Treatment Of Depression
EP2248519A3 (en) Non-mucoadhesive film dosage forms
JP2018507243A5 (enExample)
JP2019517542A5 (enExample)
JP2016074728A (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および/または神経精神医学的障害を改善するための4−アミノピリジンの使用
JP2019530706A5 (enExample)
Gautam et al. Evaluation of the efficacy of methylprednisolone, etoricoxib and a combination of the two substances to attenuate postoperative pain and PONV in patients undergoing laparoscopic cholecystectomy: a prospective, randomized, placebo-controlled trial
JP4996803B2 (ja) 抗高血圧剤に対する抵抗性及び関連状態を処置する方法及び処方物
RU2013130926A (ru) Комбинированная терапия, включающая вемурафениб и интерферон, для применения в лечении рака
US20210353648A1 (en) Grapiprant unit dosage forms
RU2008102911A (ru) Фармацевтические составы на основе гуанфацина, подходящие для ежедневного введения в виде единичной дозированной формы
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
CN104936585B (zh) 包括苯肾上腺素和扑热息痛的组合药剂
JP6420923B1 (ja) 医薬
RU2394559C2 (ru) Способ установления неспецифического противоинфекционного действия иммуномодулирующего иммунобиологического препарата
Vo et al. Guidelines for the Use of Parkinsonian Drugs (in USA)
CN103635194A (zh) 用于治疗早泄的药物组合物以及用于治疗早泄的方法

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20121009